99 related articles for article (PubMed ID: 3770045)
21. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
Kokoschka EM; Luger T; Micksche M
Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
[TBL] [Abstract][Full Text] [Related]
22. Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma.
Samson MK; Baker LH; Talley RW; Fraile RJ; McDonald B
Cancer Treat Rep; 1978 Aug; 62(8):1223-5. PubMed ID: 356980
[TBL] [Abstract][Full Text] [Related]
23. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
24. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy with a nitrosourea-based protocol in advanced malignant melanoma.
Karakousis C; Blumenson L
Eur J Cancer; 1993; 29A(13):1831-5. PubMed ID: 8260235
[TBL] [Abstract][Full Text] [Related]
26. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
27. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of bleomycin, actinomycin D, DTIC and vindesine in disseminated malignant melanoma.
Mulder NH; Sleijfer DT; Smit JM; De Vries EG; Willemse PH; Koops HS
Eur J Cancer Clin Oncol; 1986 Jul; 22(7):879-81. PubMed ID: 2429842
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
30. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
[TBL] [Abstract][Full Text] [Related]
31. Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
York RM; Foltz AT
Cancer; 1988 Jun; 61(11):2183-6. PubMed ID: 2452681
[TBL] [Abstract][Full Text] [Related]
32. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
33. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
34. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
Halpern J; Catane R; Biran S; Fuks Z
Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
[No Abstract] [Full Text] [Related]
35. Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Carmo-Pereira J; Costa FO; Henriques E
Eur J Cancer Clin Oncol; 1986 Dec; 22(12):1435-9. PubMed ID: 3595669
[TBL] [Abstract][Full Text] [Related]
36. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
37. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
[TBL] [Abstract][Full Text] [Related]
38. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
[TBL] [Abstract][Full Text] [Related]
39. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
Hoffmann R; Müller I; Neuber K; Lassmann S; Buer J; Probst M; Oevermann K; Franzke A; Kirchner H; Ganser A; Atzpodien J
Br J Cancer; 1998 Oct; 78(8):1076-80. PubMed ID: 9792153
[TBL] [Abstract][Full Text] [Related]
40. The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Young DW; Lever RS; English JS; MacKie RM
Cancer; 1985 May; 55(9):1879-81. PubMed ID: 2579722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
